Dr. Umar

In DSS-induced UC rats, D-limonene reduced disease severity and suppressed NF-κB-driven cytokines, COX-2/PGE2, iNOS, MMP-2/9, while improving SOD/GSH and restoring p-ERK1/2. No microbiome data were collected, but pathways align with microbe-triggered inflammation biology.

In an E. coli mouse model, lemon essential oil reduced oxidative stress, cytokines, and duodenal damage while restoring tight junction gene expression. Whole-oil LEO outperformed high-purity d-limonene at similar doses, implying multi-terpene synergy relevant to barrier-focused microbiome phenotyping.

In a mouse CDAD model, carvacrol reduced diarrhea and clinical severity while shifting the microbiome away from Proteobacteria/Enterobacteriaceae blooms and toward Lactobacillaceae/Lachnospiraceae enrichment, without markedly decreasing alpha diversity—highlighting a potential microbiome-sparing prophylactic strategy.

This review explains how plants and microbes produce terpenes and isoprenoids via MVA/MEP pathways and why their chemical diversity supports ecology, therapeutics, nutraceuticals, fragrances, and biofuels. It is microbiome-adjacent through antimicrobial and immunomodulatory bioactivity.

Transferrin is the plasma iron-binding protein that delivers iron to tissues while restricting microbial access to this essential nutrient. Through transferrin receptors and nutritional immunity, transferrin links iron homeostasis to immune defense and microbiome ecology.

This study shows hepcidin cleanly distinguishes ACD from ACD/IDA and predicts oral iron responsiveness. High hepcidin locks iron in macrophages and blocks absorption; low hepcidin restores ferroportin, absorption, and mobilization—an iron-state signature relevant to microbiome ecology.

This review explains how luminal iron availability reshapes gut microbial communities, often enriching Enterobacteriaceae and reducing Bifidobacterium/Lactobacillus, with downstream effects on SCFAs, oxidative stress, inflammation, IBD severity, and pathogen fitness. Iron route (oral vs IV) matters clinically.

This study shows that transferrin-mediated iron sequestration drives nutritional immunity in Drosophila. Toll/Imd pathways induce Tsf1, causing infection-associated hypoferremia. Tsf1 loss increases susceptibility to Pseudomonas and Mucorales, and makes pyoverdine dispensable due to excess iron.

This review on transferrin receptor 1 iron uptake explains how TfR1 imports transferrin-bound iron and how IRP/IRE, HIF, miRNAs, and trafficking pathways tightly regulate receptor levels. These host iron controls indirectly shape microbiome ecology by governing iron availability that selects for iron-scavenging microbes.

Cytochrome c-549 cyclic photophosphorylation in Anacystis nidulans is strongly dependent on redox poise, peaking at ~50% reduced cofactor. Inhibitors implicate plastoquinone and cytochrome f, while CO selectively blocks the cytochrome c-549 pathway.

This review explains how human transferrin binds and releases iron, how receptor-mediated cycling controls delivery, and how transferrin variants and post-translational modifications can disrupt iron handling. These mechanisms shape nutritional immunity and influence transferrin and microbiome interactions via microbial iron competition.

Hepcidin is a liver peptide hormone that controls systemic iron by binding ferroportin and limiting iron export. Inflammation and microbial signals can increase hepcidin, promoting iron restriction and anemia of inflammation. Hepcidin is clinically useful for microbiome-informed evaluation of iron disorders.

This review explains how inflammation drives anemia via hepcidin-mediated iron sequestration, impaired iron absorption, and suppressed erythropoiesis, framing AI as “nutritional immunity.” It highlights diagnostic pitfalls with coexisting iron deficiency and summarizes current and emerging hepcidin-targeted treatments.

This minireview synthesizes how gut dysbiosis and hepcidin-driven iron mismanagement reinforce hepatic inflammation and stellate-cell activation in fibrosis, highlighting SCFAs, LPS/TLR4 signaling, and microbiota effects on intestinal iron transport as actionable pathways.

This study shows that IL-6-dependent hepcidin induction is a dominant host response to both bacterial (S. pneumoniae) and viral (influenza PR8) pneumonia, and to several TLR ligands, with IL-6 knockout or antibody blockade largely abolishing hepcidin upregulation.

This mechanistic study shows IL-6 directly induces hepcidin transcription via STAT3 binding to a defined promoter element (CE9) in hepatocyte-like cells, explaining a key pathway for anemia of inflammation and offering a framework for integrating inflammatory iron restriction into microbiome-related clinical interpretation.

This study showed that hepcidin ferroportin internalization is driven by direct binding of hepcidin to ferroportin, triggering lysosomal degradation and blocking iron export. The mechanism explains inflammatory hypoferremia and iron-loading disorders, although no microbiome taxa were assessed.

This review explains how hepcidin and ferroportin govern systemic iron absorption, recycling, and inflammation-driven iron restriction. It reframes iron overload and anemia syndromes as disorders of hepcidin deficiency or excess, with direct implications for diagnosis, therapy, and microbial iron ecology.

Hepcidin urinary antimicrobial peptide is a liver-derived, disulfide-rich peptide found in urine that kills select bacteria and inhibits fungal growth. It is primarily expressed in the liver, exists as multiple processed isoforms, and shows salt-sensitive antimicrobial activity relevant to host–microbe interactions.

LEAP-1 is a newly discovered, liver-expressed antimicrobial peptide found in human plasma. It is a 25–amino acid, four–disulfide peptide with strongest activity against Gram-positive bacteria and yeast, suggesting a liver-linked innate immune mechanism that may shape microbiome composition.

Aflatoxin is a carcinogenic foodborne mycotoxin that damages the liver through DNA-reactive metabolites. It also disrupts gut microbiome metabolism and gut–liver signaling, potentially contributing to inflammation and barrier dysfunction. Microbiome medicine integrates exposure biomarkers with microbial and metabolic signatures for risk assessment.

This study shows that aflatoxin B1 detoxification can be achieved by Bacillus amyloliquefaciens WF2020, mainly via thermostable extracellular enzymes, while also suppressing Aspergillus flavus aflatoxin gene expression and eliminating toxin production. Safety assays supported low toxicity.

Aflatoxin B1 gut microbiota metabolism is disrupted in F344 rats, with dose-dependent loss of fecal metabolites, reduced SCFAs and polyamines, and major pathway derangements (amino acids, pantothenate/CoA, pyruvate). Eight indicator metabolites form a predictive fecal signature of microbiota-dependent metabolic toxicity.

A mechanistic review of how aflatoxin B1 (a fungal toxin) is activated by CYP3A4 into a DNA-reactive epoxide and detoxified mainly by GSTs, especially GSTM1-1. Epoxide hydrolase contributes little. Chemoprevention may work by inhibiting P450s and inducing GSTs.